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a b s t r a c t
Repetitive non-reentrant ventriculo-atrial synchrony (RNRVAS) is a pacemaker-induced arrhythmia that
must be distinguished from atrial ﬁbrillation (AF). Pacemaker-induced arrhythmias are commonly
detected as atrial high rate episodes (AHRE) by implanted cardiac devices. Two main types of atrial
oversensing are recognized: far-ﬁeld R-wave (FFRW) oversensing and pacemaker-induced arrhythmias,
which include pacemaker-mediated tachycardia and RNRVAS. The presence of ventriculo-atrial conduc-
tion is required for both types of pacemaker-induced arrhythmias. The incidence of RNRVAS can increase
with the use of various device settings and functions, such as long atrioventricular (AV) interval
programming, the rate-adaptive mode, and the atrial overdrive pacing algorithm. The negative aspects of
pacemaker-induced arrhythmias, especially RNRVAS, include (1) loss of optimal AV delay, (2) inap-
propriate increase in ventricular pacing, (3) induction of atrial arrhythmias, and (4) inaccurate diagnosis
of AHRE. We review the incidence of arrhythmias, electrophysiological mechanisms, and the clinical
diagnosis of RNRVAS identiﬁed by using dual-chamber implantable cardiac devices.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
The atrial high rate episode (AHRE) diagnostic function of
implantable cardiac devices is often used to detect atrial
tachyarrhythmias (ATA). However, its reliability and characteristics
vary, depending on the device settings and use of other functions,
such as the rate-adaptive mode or the atrial overdrive pacing
(AOP) algorithm, especially in dual-chamber devices. The “ASymp-
tomatic atrial ﬁbrillation and Stroke Evaluation in pacemaker
patients and the atrial ﬁbrillation Reduction atrial pacing Trial”
(ASSERT) examined the impact of device-detected, subclinical
ATA on the development of strokes and systemic embolisms
[1,2]. In that study, the presence of subclinical ATA was associated
with a signiﬁcant 2.5-fold higher risk of thromboembolic events in
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pacemaker or ICD recipients [2]. The diagnosis of subclinical ATA
based on the presence of AHRE is critical information that should
prompt the initiation of appropriate preventive therapies, such as
long-term oral anticoagulation or antiarrhythmic medications.
The presence of AHRE, however, may not invariably indicate
the presence of ATA. We have recently reported AHRE that
reﬂected episodes of atrial ﬁbrillation (AF) as well as device-
mediated arrhythmic events, such as repetitive non-reentrant
ventriculo-atrial synchrony (RNRVAS), pacemaker mediated tachy-
cardia (PMT), and far-ﬁeld R wave (FFRW) oversensing, particu-
larly in the presence of long atrioventricular (AV) intervals in the
DDD mode, or when rate-responsive pacing or an AOP algorithm
was used in recipients of a dual-chamber pacemaker or an
implantable cardioverter deﬁbrillator [3]. RNRVAS or PMT require
ventriculo-atrial (VA) conduction to develop.
2. Atrial setting in dual-chamber devices
An optimal setting of atrial sensitivity is key for the accurate
detection of ATA by implantable dual-chamber pacing devices. To
optimize AF detection and lower the risk of atrial undersensing by
dual-chamber implanted devices, a setting of a o0.5 mV atrial
sensitivity is usually recommended. The setting of a low atrial
sensitivity lowers the risk of FFRW oversensing as well as lowering
the chances of detecting ATA, due to undersensing the atrial
electrogram during ongoing tachyarrhythmia. In this case, the
incidence of ATA may be underestimated. Conversely, a setting of
high atrial sensitivity increases the chances of detecting ATA and
increases the likelihood of FFRW oversensing, in which case the
incidence of clinical ATA may be overestimated. Although the
optimal atrial sensitivity remains to be deﬁned, a o0.5 mV setting
is generally recommended for recipients of implantable devices
who have a history of AF. However, high atrial sensitivity settings
might cause atrial oversensing. Table 1 shows the pitfalls for
diagnosing AF. In the presence of atrial undersensing (when the
atrial sensitivity is low), the incidence of true AF cannot be
detected accurately. Atrial oversensing may result in (1) double
counts of the P wave, which includes RNRVAS and FFRW over-
sensing, or (2) sensing of myopotentials, lead noise, or electro-
magnetic interference. Atrial undersensing and oversensing may
both interfere with the diagnosis of true AF.
3. Device-detected non-atrial ﬁbrillation
State-of-the-art, implantable, dual-chamber cardiac devices pro-
vide useful diagnostic information, including the number and
duration of automatic mode switch (AMS) episodes upon detecting
ATA. However, to collect accurate diagnostic information, special
attention must be paid to the device settings, to the presence versus
absence of VA conduction, which when present, often represents
RNRVAS or PMT, to the post-ventricular atrial blanking period
(PVAB) and atrial sensitivity, and to the sensing of FFRW in the
atrial channel. Preventing FFRW sensing by the atrial channel is
challenging as it is inversely correlated with the duration of the
PVAB and with the atrial sensitivity. Furthermore, the presence of
VA conduction may cause RNRVAS or PMT. Although FFRW sensing,
RNRVAS, and PMT are not ATA, they (a) are counted as ATA episodes
by implantable monitoring devices, (b) might be the source of
inaccurate diagnostic information and inappropriate AMS from DDD
to DDI or VVI mode, and (c) may trigger ATA or cause pacemaker
syndrome [4–14]. The clinical shortcomings associated with atrial
oversensing are shown in Fig. 1.
Increasing the duration of PVAB might be an effective means of
preventing FFRW oversensing in the atrial channel. However, this
narrows the search window of atrial sensing, and shortens the
window of ATA detection, which might decrease the likelihood of
detecting ATA. Conversely, a short PVAB widens the search
window of atrial sensing and of ATA detection, a setting that
might decrease the speciﬁcity of ATA detection. In clinical practice,
therefore, a þ25 ms PVAB setting between the ventricular pacing
spike and FFRW sensing is generally recommended [15].
Table 1
Atrial sensing in dual-chamber devices.
Atrial undersensing
 True atrial ﬁbrillation
 Functional atrial ﬁbrillation
Atrial oversensing
 Repetitive non-reentrant VA synchrony (RNRVAS)
 Pacemaker mediated tachycardia (PMT)
 Far-ﬁeld R wave (FFRW) oversensing
 Myotonic potentials
 Lead failure
 Electromagnetic interference
 Other
Inappropriate mode switch 
Automatic conversion to DDI mode
Pacemaker syndrome
due to AV dyssynchrony
New onset AF
Inaccurate Diagnosis
AHRE
AF burden
number of AMS
Inappropriate therapies
Misdiagnosis of ATA
Delayed anti-tachycardia pacing or 
ICD shock Decreased Cumulative %Vp in CRT
Fig. 1. Adverse effects of atrial oversensing. AHRE, atrial high rate episode; ICD, implantable cardioverter deﬁbrillator; CRT, cardiac resynchronization therapy; AF, atrial
ﬁbrillation; AV, atrioventricular; AMS, auto mode switch; Vp, paced ventricular event.
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Endless loop tachycardia, which might present as PMT or
RNRVAS, both mediated by VA conduction, is a well known,
understood, and relatively common complication associated with
implantable dual-chamber cardiac devices. While PMT is the most
commonly observed pacemaker-induced tachyarrhythmia, RNRVAS,
also known as AV desynchronization arrhythmia or VA synchrony
non-reentrant arrhythmia, may cause symptoms indistinguishable
from those caused by PMT [16–18].
The occurrence of RNRVAS, ﬁrst reported as an isolated case in
1985 [16], have since been conﬁrmed in dual-chamber pacemaker
recipients undergoing 24-h ambulatory electrocardiograms, who
report symptoms similar to those of patients suffering from pace-
maker syndrome [17,18].
4. Incidence of RNRVAS
RNRVAS is not an uncommon observation in dual-chamber
pacemaker or ICD recipients [17,19]. We studied 39 patients who
had neither histories nor occurrences of ATA before receiving dual-
chamber pacemakers that were programmed in the DDD mode
with AHRE set at 4190 beats per minute (bpm) after implantation
[14]. An atrial overdrive pacing (AOP) algorithm was randomly
programmed “ON” in 19 and “OFF” in 20 patients. Of 1528 AHRE,
257 were available for analysis by using intracardiac electrograms
(iEGM). Seventy-six episodes occurred with the AOP algorithm
“OFF” and 181 occurred with the AOP algorithm “ON”. Surprisingly,
109 of the 257 episodes (42%) were attributable to RNRVAS instead
of AF episodes. In the AOP algorithm “OFF” group, 76 of 76
episodes (100%) were true ATA, whereas in the AOP algorithm
“ON” group, 109 of 181 episodes (60%) were due to RNRVAS. The
speciﬁcity of true ATA detection by using AHRE was 40% when the
AOP algorithm was activated, versus 100% when it was not used,
unequivocally conﬁrming the signiﬁcantly higher incidence of
RNRVAS associated with the AOP activation.
Among 2343 pacemaker recipients followed up for a mean of
2.5 years in the ASSERT trial, 50% were randomly assigned to
activation of the AOP algorithm, whereas in the other 50%, the
algorithm was turned off [20]. The rate of false positive automatic
detection of AF was 23.0% in the group assigned to the algorithm
“ON”, versus 7.7% in the group assigned to the algorithm “OFF”
(relative risk 2.99; 95% CI 2.40–3.74; Po0.001). The cause of false
positive automatic ATA detection was mainly due to 226 episodes
of RNRVAS occurring in the AOP algorithm “ON” group, compared
with 47 episodes in the AOP algorithm “OFF” group (P¼0.001).
5. Electrophysiological mechanisms of RNRVAS
The electrophysiological mechanisms of RNRVAS have been
thoroughly studied [17,21,22]. In dual-chamber pacing, it is usually
observed in the presence of (1) VA conduction and retrograde P
wave sensed within the post-ventricular atrial refractory period
(PVARP), (2) additional programming in rate-adaptive mode or use
of an AOP algorithm to prevent AF, and (3) programming of a long
AV interval to prevent intrinsic AV conduction. The following
additional conditions leading to the occurrence of RNRVAS are
also notable: (1) setting of a long PVARP, (2) the presence of a long
VA conduction time, (3) the presence of a long myocardial atrial
refractory period, and (4) programming of a high lower pacing
rate limit.
Fig. 2 illustrates a common trigger of RNRVAS by a premature
ventricular complex (PVC) propagating through the AV node and
arriving at the atrium within the PVARP. If the AOP algorithm has
been activated, the premature event is recognized as a premature
atrial complex within the PVARP, causing early atrial pacing by the
algorithm. However, this early pacing attempt might fall in the
atrial refractory period, particularly in the presence of prolonged
atrial refractoriness, for instance in the case of treatment with
antiarrhythmic drugs. Although this ineffective atrial pacing does
not activate the atrium, ventricular pacing occurs in programmed
AV intervals in DDD or DDI modes. This ventricular-paced event
propagates through the AV node retrogradely and activates the
atrium. These cyclic atrial and ventricular depolarizations will be
repeated continuously. The pacemaker will count 2 atrial (the ﬁrst
from retrograde conduction by a PVC or by ventricular pacing and
the second from ineffective atrial pacing) and 1 ventricular paced
Ap Ap
Vp
Vs
PVC
PVARP
AV delay
Atrial RP
Retrograde P wave 1
2
PVARP3
Ap
Ineffective atrial stimulus5
Atrial RP4
AV delay6
Vp7
Retrograde P wave 1
Fig. 2. Electrophysiological mechanism of repetitive non-reentrant ventriculo-atrial synchrony (RNRVAS). The retrograde P wave [1] from the PVC fell within the PVARP [2],
which needs to be long enough [3]. After the atrial activation, the atrial refractoriness by the retrograde P wave persists [4]. The next early paced atrial event fell within the
atrial refractory period, and that paced atrial event is ineffective [5]. After the ineffective atrial stimulus, a new timing cycle begins [6] and a paced ventricular event [7]
occurs after the programmed atrioventricular interval. These cycles continue repetitively. Vp, paced ventricular event; Vs, sensed ventricular event; Ap, paced atrial event;
As, sensed atrial event; PVARP, post-ventricular atrial refractory period; PVC, premature ventricular contraction; RP, refractory period.
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event. Thus, during RNRVAS, an atrial sensed and a non-captured
atrial paced event occurs cyclically with ventricular paced event.
Fig. 3 shows an example of RNRVAS in a dual-chamber pace-
maker recipient with sinus node disease, with the pacemaker set
in rate adaptive DDI-R mode pacing with an AV interval of 300 ms
and lower rate limit of 60 ppm. The tracing shows sensor-driven
DDIR pacing at 80 bpm (V–V cycle length¼750 ms). Ventricular
captures are conducted in a retrograde manner through the AV
node, and the atrial events are sensed within the PVARP after a
220-ms VA conduction time. Rate adaptive atrial pacing is driven
by a sensor at a rate of 80 ppm. Since the interval between the
sensed retrograde P wave within the PVARP and the next atrial
paced event is only 200 ms, the pacing stimulus does not capture
the atrium. Ventricular pacing follows ineffective atrial pacing at
the programmed AV delay of 320 ms. RNRVAS continues as long as
the sensor-driven rate response is 480 ppm. However, after
gradual slowing of sensor-driven pacing, the interval between
the sensed P wave within the PVARP and the atrial paced event
lengthens to 4250 ms, allowing successful capture of the atrium
(n), return to intrinsic AV conduction, and then terminate without
VA conduction [23]. In this case, RNRVAS was induced with rate
adaptive DDI-R pacing and observed in the setting of acceleration
of sensor-driven DDD or DDDR dual-chamber pacing with long AV
intervals [17,19].
Another example of RNRVAS, induced by the AOP algorithm set
for the prevention of AF in DDD mode, is shown in Fig. 4 [3,14].
The retrograde P wave after ventricular pacing falls within the
PVARP, activating the AOP algorithm. Since the interval between
the sensed retrograde P wave and the next atrial paced event
initiated by the AOP algorithm is very short, the atrial pacing
stimulus falls in the atrial refractory period and fails to capture the
atrium. Ventricular pacing after a programmed AV interval
long enough for recovery of the atrial myocardium allows repeti-
tive VA conduction and perpetuation of RNRVAS. While RNRVAS is
not common, it is generally observed in the presence of VA
conduction and retrograde P waves sensed within the PVARP,
after ventricular pacing triggers the AOP algorithm, and when a
relatively long AV interval has been programmed to limit
Fig. 3. Repetitive non-reentrant ventriculo-atrial synchrony (RNRVAS) induced by sensor-driven, rate-adaptive dual-chamber pacemaker. Top tracing: bipolar atrial
electrogram channel (recorded between the tip and ring electrodes of the atrial lead). Bottom tracing: marker channel. VP, ventricular pacing; AS, atrial sensing (falling
within the PVARP); AP, atrial pacing; ATA, device counts as ATA detection.
Fig. 4. Repetitive non-reentrant VA synchrony (RNRVAS) induced by atrial overdrive pacing algorithm. The retrograde P wave after ventricular pacing falls within the PVARP.
Atrial overdrive pacing falls immediately after the sensed retrograde P wave. However, since the interval between that sensed P wave and the next paced atrial event is very
short, the stimulus falls in the atrial myocardial refractory period and fails to capture the atrial myocardium. Ventricular pacing after an AV interval long enough for the atrial
recovery allows the next retrograde VA conduction, resulting in sustained RNRVAS. Top tracing, marker chains; bottom tracing, intracardiac electrogram (iEGM). V, paced
ventricular event; A, paced atrial event; P, sensed atrial event falling within PVARP; Atip-Aring, bipolar atrial recording between tip and ring of the atrial lead.
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unnecessary ventricular pacing, particularly in instances of sinus
node disease.
6. Clinical diagnosis of RNRVAS
RNRVAS is usually diagnosed by recording a 12-lead or a 24-h
ambulatory electrocardiogram and is conﬁrmed by interrogating the
iEGM data stored in the pacemaker memory. It rarely causes
symptoms, although it might emulate pacemaker syndrome. In most
cases, RNRVAS is detected at the time of scheduled ambulatory visits.
Technologic advances in state-of-the-art pacemakers have facili-
tated the detection of RNRVAS, as the detection algorithm for AHRE
is capable of counting both atrial sensed and paced events within the
atrial refractory period.
7. Clinical implications
The potential adverse effects of RNRVAS are shown in Fig. 1 and
include: (1) loss of optimal AV delay, (2) inappropriate increase in
ventricular pacing, (3) trigger of atrial arrhythmias, (4) inaccurate
diagnosis of AHRE, and (5) loss of optimal AV conduction by
automatic switch from DDD to DDI or VVI modes. These adverse
effects might increase unnecessary ventricular pacing and might
affect ventricular function, especially in pacemaker recipients who
present with sinus node disease and preserved AV conduction. The
loss of optimal AV delay with RNRVAS causing pacemaker
syndrome-like symptoms has been reported [24]. Furthermore,
the repetitive occurrence of RNRVAS may cause AF (Fig. 5). In this
case, the transition from sustained RNRVAS to AF was conﬁrmed.
It is essential to distinguish between true AF and pacing-induced
atrial arrhythmias when evaluating iEGMs of AHRE in clinical
practice. Misdiagnosing AF in a case in which the true etiology is
pacing-induced atrial arrhythmia, might lead to the use of antic-
oagulation therapies in pacemaker patients without true AF.
8. Summary
ATA are very common in recipients of implanted cardiac
devices, and the detection of true AF, indicated by the presence
of AHRE, is a useful diagnostic function of these devices. However,
physicians should be aware that although AHRE can indicate true
AF, the etiology can also be RNRVAS, PMT, and FFRW oversensing.
Therefore, iEGM is a useful diagnostic tool available in advanced
implanted cardiac devices.
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